Stoke Therapeutics
STOK
47 hedge funds and large institutions have $409M invested in Stoke Therapeutics in 2019 Q2 according to their latest regulatory filings, with 47 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
45.24% more ownership
Funds ownership: 0% → 45.24% (+45%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$90.1M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$50.2M |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$50M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$30.1M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$27.4M |
Top Sellers
STOK Hedge Fund Activity: Q2 2019 in Review
47 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q2 2019, worth a combined $409M.
Buyers outnumbered sellers: 47 funds opened new STOK positions and 0 closed out — a net gain of 47 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RTW Investments, opening a new position worth an estimated $90.1M.
- 47 institutional investors held Stoke Therapeutics (STOK) as of Q2 2019, up from 0 in Q1 2019.
- Funds reported $409M of Stoke Therapeutics stock for Q2 2019.
- 47 funds opened new Stoke Therapeutics positions in Q2 2019 and 0 closed out, a net change of +47 holders.
- The largest Stoke Therapeutics buyer in Q2 2019 was RTW Investments, an estimated $90.1M added.
Based on aggregated 13F filings for Q2 2019.